Read More Pharma Industry News Genentech’s Alecensa shows promise in Phase III ALINA study for early-stage ALK-positive NSCLC Genentech, a Roche Group member, has announced positive results from its Phase III ALINA study evaluating Alecensa (alectinib),… byPallavi MadhirajuSeptember 3, 2023